Inovio Pharmaceuticals Inc (INO)

[ppnlf]

So TheStreet publishes a new report rating INO as a sell. Yet another hatchet job.
Main reasons given are
1. INO share price has risen over the past year (is that a reason to sell?)
2. EPS has improved and should continue to grow (is that a reason to sell?)
3. Net operating cash-flow for Q2 has declined to -$5.56m compared to 2013 (the 10-Q says 6 month net operating cash-flow of -$13.7m vs -$10.6m which is what you would expect given the development stage of INO - no mention by TheStreet of the improvement in cash from $52.7m at 12/13 to $109m at 6/14. Is this a reason to sell?)
4. They say the return on equity has slightly decreased quarter on quarter (and this is meaningful for a company at this pace of change and a reason to sell?)
5. They say that net income has under performed compared to S&P500 and biotech sector (net loss for INO was $10.87m for Q2/13 and $10.71m for Q2/14. Is this a reason to sell)

All this shows me is that TheStreet writes and the market reacts. Headless chickens come to mind.